Biopharmaceuticals
Development, manufacturing and analytics of monoclonal antibodies and other proteins
- Excellent speakers, different perspectives
- Compact knowledge transfer
- All course days can be booked individually
- Including learning assessment
- Officially certified according to ISO 9001+21001
Online-Seminar
From
1.290,00 €
plus VAT
Services & Process
Veranstaltung - 1.290,-€ zzgl. MwSt.
The participation fee includes documentation for download, a certificate, access to the Learning Space and technical support including PreMeeting.
Period:
Each day from 9:00 am - 5:00 pm CET - Online training
You may dial in 30 minutes before the lecture starts
Booking details
Online-Seminar
From
1.290,00 €
plus VAT
Services & Process
Veranstaltung - 1.290,-€ zzgl. MwSt.
The participation fee includes documentation for download, a certificate, access to the Learning Space and technical support including PreMeeting.
Period:
Each day from 9:00 am - 5:00 pm CET - Online training
You may dial in 30 minutes before the lecture starts
The compact course with a content focus on the development, production and analytics of biotech drugs. Secure your place and qualify now! All three course days can be booked individually (single day = 1.290€ plus VAT) - for booking, please contact us!
Your speakers
What to Expect
- Development & manufacturing on 2 December 2026:
- Manufacturing process
- Formulation Process changes Regulatory requirements on 3 December 2026:
- IMPD quality part
- Non clinical aspects Regulatory update: Biologics and biosimilars Biopharmaceutical analytics on 4 December 2026:
- Method validation
- Stability testing
- Specifications
Who Should Attend
This course is aimed at specialists and managers in the pharmaceutical industry who are involved in the development, production and analysis of biotechnological drugs.
The focus on all three days will be on familiarising you with the regulatory framework with reference to guidelines.
In particular, employees in the departments of research & development, regulatory affairs, manufacturing, analytics, quality assurance and quality control will benefit from attending.
Objective of the Event
After day 1, you will be familiar with the specialties of galenic development process technologies and you will know what to look out for in process changes and comparability studies.
After day 2, you will be aware of critical quality parameters of biologics and biosimilars and know the challenges of the non-clinical program.
After day 3, you will have gained expertise in method validation, stability testing and specification writing.
Following Day 3, you will receive the access data for the optional online test for learning success control by e-mail.
Your Benefit
- You know the current regulatory requirements for the (non-)clinical development of biologics and biosimilars
- You know critical quality parameters of biopharmaceuticals
- You know which data are required for the IMPD compilation and the quality documentation
- You know specifics of proteins and what challenges to overcome in formulation development
- You know which requirements exist for the manufacturing process of active ingredients and finished medicinal products - from clinical development to marketing authorisation - and you are familiar with the corresponding process technologies
- You can implement comparability requirements in case of changes
- You will be able to implement regulatory requirements for analytics, including method development/validation and setting and justifying specifications
- You know the requirements for stability testing according to ICH and for method validation according to FDA
Programme
each day from 9:00 am till 5:00 pm
Day 1
Dr Josef Gabelsberger
- Production systems: Requirements
- Practical challenges in development and manufacturing
Dr Monika Geiger
- Peculiarities of proteins
- Formulation development
- Analytics for formulation development
- Requirements for primary packaging materials
Dr Jörg Engelbergs
- Active substance characterisation and impurity profiles
- Definition of specifications and acceptance criteria
Dr Jörg Engelbergs
- Demonstration of comparability during clinical development: requirements
- Comparability exercise according to guideline ICH Q5E: Demonstration of comparability after approval
- Ensuring regulatory compliance - change control: Variations & PACMPs
Manufacturing process of the protein active ingredient
Manufacturing process of the protein active ingredient
Dr Josef Gabelsberger
- Production systems: Requirements
- Practical challenges in development and manufacturing
Bio break
From active substance to protein formulation
From active substance to protein formulation
Dr Monika Geiger
- Peculiarities of proteins
- Formulation development
- Analytics for formulation development
- Requirements for primary packaging materials
Lunch break
Active ingredient/finished drug product manufacturing process (from clinical development to MA): Requirements
Active ingredient/finished drug product manufacturing process (from clinical development to MA): Requirements
Dr Jörg Engelbergs
- Active substance characterisation and impurity profiles
- Definition of specifications and acceptance criteria
Bio break
Comparability studies for manufacturing process changes
Comparability studies for manufacturing process changes
Dr Jörg Engelbergs
- Demonstration of comparability during clinical development: requirements
- Comparability exercise according to guideline ICH Q5E: Demonstration of comparability after approval
- Ensuring regulatory compliance - change control: Variations & PACMPs
End of seminar day 1
Day 2
Dr Sonja Matt
- Scope of the documentation
- Status of process validation and analytical methods
- Stability of IMP
- Approaches for CTA (history and future)
Dr Anika Schröter
- Standard requirements and deviation from the standard ("case-by-case")
- Considerations for the determination of the starting dose in humans
Dr Anika Schröter
Dr Sonja Matt
- Requirements for the evaluation of biosimilars
- Definition of the similarity rank
- Dealing with/and (non-)acceptance of differences
Dr Anika Schröter
- Regulatory requirements
Dr Sonja Matt
- Process validation: Innovations
- Product and process development: QbD
- Immunogenicity: Assessment
- ICH Q12 & post approval change management protocol (PACMP)
Requirements for the IMPD quality part
Requirements for the IMPD quality part
Dr Sonja Matt
- Scope of the documentation
- Status of process validation and analytical methods
- Stability of IMP
- Approaches for CTA (history and future)
Biologics: Non-clinical aspects I
Biologics: Non-clinical aspects I
Dr Anika Schröter
- Standard requirements and deviation from the standard ("case-by-case")
- Considerations for the determination of the starting dose in humans
Lunch break
Biologics: Non-clinical aspects II
Update on regulatory landscape I
Update on regulatory landscape I
Dr Sonja Matt
- Requirements for the evaluation of biosimilars
- Definition of the similarity rank
- Dealing with/and (non-)acceptance of differences
Bio break
Biosimilars: Non-clinical aspects
Biosimilars: Non-clinical aspects
Dr Anika Schröter
- Regulatory requirements
Update on regulatory landscape II
Update on regulatory landscape II
Dr Sonja Matt
- Process validation: Innovations
- Product and process development: QbD
- Immunogenicity: Assessment
- ICH Q12 & post approval change management protocol (PACMP)
Recap, Q&As and end of seminar day 2
Day 3
Dr Matthias Germer
Dr René Thürmer
- Validation of protein analytical methods
- Qualification of impurities in active ingredients and finished products
- Typical dossier deficiencies
Dr Matthias Germer
- Target setting; requirements for formal stability testing according to ICH
Dr René Thürmer
Dr René Thürmer
- Implementation of the ICH Q6B Guideline
- Critical quality attributes, common errors and defects - case studies
- Contamination specifications of drug substance and drug product
- Regulations/responsibilities in the context of clinical studies/registration
Analytics for clinical IMPs
Bio break
Development and validation of analytical methods: Requirements for the registration dossier
Development and validation of analytical methods: Requirements for the registration dossier
Dr René Thürmer
- Validation of protein analytical methods
- Qualification of impurities in active ingredients and finished products
- Typical dossier deficiencies
Lunch break
Stability studies
Stability studies
Dr Matthias Germer
- Target setting; requirements for formal stability testing according to ICH
Update on ICH Q14: Development of analytical methods
Bio break
Setting, justifying and changing specifications
Setting, justifying and changing specifications
Dr René Thürmer
- Implementation of the ICH Q6B Guideline
- Critical quality attributes, common errors and defects - case studies
- Contamination specifications of drug substance and drug product
- Regulations/responsibilities in the context of clinical studies/registration
Recap and Q&As day 3
End of seminar
Downloads
Request the documents using our form.

Abbreviation list Biotech
Weitere Informationen
Booking of individual course days
All three course days can be booked individually (a single day of your choice = €1,290 plus VAT).
For booking, please contact us!
Modular qualification program for Development Expert Biologics
This seminar is the basic module of our Development Expert Biologics qualification programme.
The course concept:
- You attend our basic course "Biopharmaceuticals"
- Afterwards you will take part in 3 further seminar modules (= 3 seminar days), which you can put together individually from the course curriculum
- You will receive structured further training and comprehensive knowledge on topics relating to the development and production of biologics
- You can specialise according to your main area of activity through the targeted selection of seminars
For more information, please visit our Website
Benefits of a FORUM Institut training course
FORUM Institut’s all-in-one training platform uses the latest teaching methods.
All our online training courses take place in the Learning Space, our holistic learning environment with many features that promote effective and sustainable learning.
- Live and interactive learning on our Learning Space training platform
- A platform with many features: events rooms, chat, course agendas and documents, surveys, workshop rooms and much more
- Easy surveys with Slido
- ‘Deluxe’ chat: group chats, one-to-one chats, one-to-one video chats
- A central repository for documents and media
- Other services and apps such as Padlet and Mentimeter available directly on the platform
- The perfect marriage of teaching methods and technology
- High level of interactivity with plenty of opportunity for questions
- Continuous support throughout the event to ensure the most effective learning
- Free technical pre-meeting to start off your training on the right foot
Free pre-meeting and technology check
You can attend one of our pre-meetings and explore our Learning Space free of charge. Registration is not required. You can find available dates for a pre-meeting in your customer portal. Click the green ‘Participate’ button in the pre-meeting in the customer portal and you will be redirected to the Learning Space.
The pre-meeting gives you the opportunity to explore our Learning Space and to familiarise yourself with the technology to start off your online training on the right foot. This is a non-binding offer for all our customers and not a prerequisite for participation. If a pre-meeting date does not suit you but you would still like a technology check, please contact us.
This is what distinguishes this event
Modules
Hours of learning content
Our Recommendations
Further Information
Your Contact Person
We are happy to advise you personally and individually.
Dr. Birgit Wessels
Conference Manager
+49 6221 500-652
b.wessels@forum-institut.de






